English
Regional settings| Spread | 0.23 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 65.87 |
| Open | 65.74 |
| 1-Year Change | 75.49% |
| Day's Range | 65.74 - 67.07 |
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, oncology products (anti-cancer), hormones and steroids, and complex formulations. The Company’s products include both branded and generic pharmaceuticals. Its generic products include Aspirin and Extended Release Dipyridamole, Bretylium Tosylate Injection USP, cholestyramine, Etodolac, Fluvoxamine, Indapamide, Nilutamide, Vancomycin and more. Its branded products include Arimidex (anastrozole) tablets, Atacand HCT Tablets, Atacand (candesartan cilexetil) Tablets, Casodex, Cortenema, Cortrophin gel, Cortrophin-Zinc, Inderal LA, Inderal XL, InnoPran XL, Lithobid, Reglan and Vancocin. It operates across three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota and one is located in Oakville, Ontario.
BRIEF: For the fiscal year ended 31 December 2021, ANI Pharmaceuticals Inc revenues increased 4% to $216.1M. Net loss applicable to common stockholders increased 90% to $42.8M. Revenues reflect Royalties from licensing agreements segment increase from $1.4M to $11.8M, Other segment increase from $783K to $1.9M, United States segment increase of 4% to $211.9M. Higher net loss reflects Selling.
6Common Stock $.0001 Par, 3/10, unlim. auth., 93,590,612 issd. Insiders own 2.43%. IPO: N/A. Cl. C Common no Par, 12/10, unlim. auth., 391,286 issd. 5/31/02 1-for-10 reverse stock split. *7/06, private placement of 3,812,978 shares @ 04/06, 1-for-6 Reverese stock split. 07/13, 1-for-6 Reverese stock split.
